Some Surprises in the European Commission’s New Intellectual Property Strategy
The European Commission's new intellectual property (IP) strategy is out and it holds a number of surprises for access to medicines. After restating the...
WHO is an essential forum for debates on intellectual property and public health
Recently, Health Policy Watch reported that some European countries at the World Health Organization (WHO) Pandemic Agreement negotiations maintain that intellectual property negotiations belong...
Written remarks submitted to the OHCHR following the Expert Workshop on the key challenges...
This blog was submitted by Dr. Katrina Perehudoff, Law Centre for Health and Rights at the University of Amsterdam, and Medicines Law & Policy,...
The People vs. AbbVie
Today, 9 May 2025, is an important day in court for the Dutch Pharmaceutical Accountability Foundation (PAF). In February 2023, PAF started a court...
BMJ Commentary: Overriding drug and medical technology patents for pandemic recovery: a legitimate move...
Interest in the use of compulsory licensing is making a comeback in high-income countries in response to concerns about access to Covid-19 vaccines and...
Wrapping up 2019 – Noteworthy Medicines Law and Policy Events
2019 had its share of noteworthy medicines law and policy events. It was also a year that saw eye-popping new levels of pharmaceutical pricing....
World Health Assembly adopts the Pandemic Agreement
"I see no objection, the resolution is adopted," said Teodoro J. Herbosa, Secretary of Health of the Philippines and President of the 78th World...
WHO Members meet to finalise the Pathogen Access and Benefit Sharing Instrument
In May 2025, the WHO member states adopted the Pandemic Agreement, but they left the work to establish an instrument for Pathogen Access and...
Medicines Law & Policy Intervention at the WHO Pandemic Accord Negotiations
This statement was delivered on 19 February at the World Health Organization in Geneva, on the occasion of the 8th Intergovernmental Negotiating Body to...
Cystic Fibrosis Medicines Wars in Europe
Monday 4 February, the UK parliament will debate the issuing of a compulsory licence by the government, called ‘Crown use’, for the cystic fibrosis...